Serina Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	8.62	3.67	7.62	0.53	0.31
Short-Term Investments	-	-	-	-	1
Cash & Short-Term Investments	8.62	3.67	7.62	0.53	1.31
Cash Growth	170.64%	-51.80%	1331.53%	-59.41%	-
Receivables	-	-	-	-	0
Prepaid Expenses	0.99	1.93	-	0.02	0.02
Other Current Assets	1.89	0.08	-	-	-
Total Current Assets	11.5	5.68	7.62	0.55	1.33
Property, Plant & Equipment	0.89	1.05	1.35	0.31	0.51
Total Assets	12.41	6.72	8.97	0.86	1.84
Accounts Payable	2.73	0.74	0.58	0.14	0.15
Accrued Expenses	1.14	1.43	0.58	0.01	0.01
Current Portion of Leases	0.16	0.19	0.25	0.13	0.21
Current Unearned Revenue	-	-	-	0.15	-
Other Current Liabilities	1.68	-	-	0.01	0
Total Current Liabilities	8.79	2.37	1.41	0.44	0.37
Long-Term Debt	-	-	2.98	1.62	-
Long-Term Leases	0.15	0.27	0.46	0.06	0.19
Other Long-Term Liabilities	1.88	3.58	-	1.08	0.95
Total Liabilities	10.82	6.22	4.86	3.19	1.51
Common Stock	0	0	-	0.02	0.02
Additional Paid-In Capital	56.99	44.96	0.88	0.65	0.64
Retained Earnings	-60.16	-44.32	-33.18	-38.45	-35.76
Total Common Equity	-3.18	0.64	-32.29	-37.78	-35.11
Minority Interest	-0.17	-0.13	-	-	-
Shareholders' Equity	1.59	0.51	4.11	-2.34	0.33
Total Liabilities & Equity	12.41	6.72	8.97	0.86	1.84
Total Debt	3.39	0.46	3.7	1.81	0.4
Net Cash (Debt)	5.23	3.21	3.92	-1.28	0.91
Net Cash Growth	-	-18.17%	-	-	-
Net Cash Per Share	0.53	0.44	0.53	-0.60	0.43
Filing Date Shares Outstanding	10.66	9.93	8.79	2.22	2.14
Total Common Shares Outstanding	10.54	9.42	2.47	2.22	2.14
Working Capital	2.71	3.31	6.21	0.11	0.96
Book Value Per Share	-0.30	0.07	-13.09	-17.03	-16.37
Tangible Book Value	-3.18	0.64	-32.29	-37.78	-35.11
Tangible Book Value Per Share	-0.30	0.07	-13.09	-17.03	-16.37
Machinery	1.09	0.97	0.87	0.38	0.37

Source: S&P Capital IQ. Standard template. Financial Sources.